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Abstract  
 
This study aimed to determine the rate-limiting step in the overall hepatic clearance 
(CLhep) of the marketed HIV protease inhibitors (PI) in rats by predicting the 
experimentally determined hepatic in vivo clearance of these drugs based on in vitro 
clearance values for uptake and/or metabolism. In vitro uptake and metabolic clearance 
values were determined in suspended rat hepatocytes and rat liver microsomes, 
respectively. In vivo CLhep was determined after intravenous bolus administration in rats. 
Excellent in vitro-in vivo correlation (IVIVC, R2 = 0.80) was observed when metabolic 
intrinsic Cl values were used, which were determined in vitro at a single concentration 
corresponding to the blood concentration observed in rats in vivo at the mean residence 
time. On the contrary, poor IVIVC was observed when in vitro metabolic Cl values based 
on full Michaelis-Menten profiles were used. In addition, the use of uptake Cl values or a 
combination of both uptake and metabolic clearance data led to poor predictions of in 
vivo clearance. Although our findings indicate a key role for metabolism in the CLhep of 
several HIV PI in rats, subsequent simulations revealed that inhibition of hepatic uptake 
can lead to altered CLhep for several of these drugs. 
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Introduction 
Prediction of in vivo clearance values of drug candidates based on in vitro data (or in 
vitro in vivo extrapolation – IVIVE - for drug clearance) has become an essential activity 
during the preclinical phases of contemporary drug development programs. As reported 
in the companion paper by De Bruyn et al. (2015), clearance predictions with in vitro 
models derived from human liver tissue allow estimating a safe first-in-human dose to 
initiate clinical trials. In vivo drug clearance prediction in rats on the other hand, as 
applied in the present paper, is useful from different perspectives. First of all, accurate 
knowledge of the pharmacokinetic behavior of drug candidates in preclinical species (as 
compared to man) supports optimal design of toxicity studies with sensible use of 
animals. Secondly, as in vivo PK profiles can also be obtained in animals via various 
routes of administration (including the intravenous route) and under standardized 
conditions for a series of compounds (cfr. the present study), in vitro in vivo comparisons 
become highly relevant and may provide opportunities to fine tune IVIVE algorithms for 
drug clearance.  
For compounds undergoing primarily hepatic elimination, in vivo clearance predictions 
are based on the extrapolation of in vitro data covering all hepatic drug elimination 
processes. These processes may include hepatic sinusoidal uptake, metabolism and/or 
biliary excretion, resulting in an entangled interplay which complicates the extrapolation 
to the in vivo situation.1,2 Additionally, drug binding and sequestration equilibria will 
affect the overall impact of these processes.  
Both microsomes and suspended hepatocytes have successfully been used for predicting 
the metabolic clearance of many compounds.3–7 However, these model systems fail to 
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quantitatively predict the in vivo clearance of drugs for which active uptake transport 
forms the rate-limiting step in the overall hepatic clearance.8 For these compounds, better 
in vitro – in vivo correlations are observed when in vitro uptake clearance values are 
measured and extrapolated to in vivo parameters.9 Thus, with the recognition that 
transport proteins can significantly influence hepatic clearance (even for compounds that 
largely depend on metabolic enzymes for their clearance), typical pharmacokinetic 
models used for IVIVE of hepatic clearance had to be modified.10 This has led to the 
development of IVIVE models implementing multiple hepatic disposition processes 
measured with various in vitro methods.11,12 Consequently, such models can be used to 
gain information about the interplay between various hepatic elimination processes and 
the rate-limiting step in the overall hepatic clearance of drugs. 
For the purpose of the present study on drug clearance prediction in rat, all marketed HIV 
protease inhibitors (PI) were included as model compounds. Since the predominant role 
of drug metabolizing enzymes in hepatobiliary disposition of HIV PI is generally 
considered as obvious, the potential role of transporters in disposition of these 
antiretroviral drugs has remained somewhat controversial. Nevertheless, interactions of 
HIV PI with transporters have been described. HIV PI are potent inhibitors of the sodium 
taurocholate-cotransporting polypeptide Ntcp 13 and several members of the organic 
anion transporting polypeptide family Oatp 14 in rat hepatocytes. In addition, HIV PI are 
substrates of several efflux transporters.15,16 Extensive metabolism by cytochrome P450 
enzymes has been explored in rat liver microsomes.17,18 Thus, a complex interplay 
between multiple processes defines the hepatic disposition and clearance of HIV PI in 
rats. By directly comparing the rate of uptake into rat hepatocytes and the rate of 
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metabolism in rat hepatocytes and rat liver microsomes, Parker and Houston indicated 
that at low substrate concentrations hepatic uptake is the rate limiting step in the overall 
hepatic clearance of nelfinavir, saquinavir and ritonavir in rats.19 In addition, they showed 
that this uptake process is extremely rapid and therefore suggested that the hepatic 
clearance of these three HIV PI is still blood flow limited in the in vivo situation.  
The aim of this study was to accurately delineate the respective roles of enzymes and 
transporters in the overall hepatic elimination of all commercially available HIV PI in 
rats. Therefore, in vitro uptake data in suspended rat hepatocytes and metabolic data in rat 
liver microsomes were extrapolated to the hepatic in vivo clearance for all HIV PI and 
compared to experimentally determined in vivo blood clearance in rats. The same 
approach was applied for this series of compounds in man (see companion paper De 
Bruyn et al., 2015), providing unique data sets for detailed cross-species comparison of 
pharmacokinetic behaviour of these compounds. At the same time, possible species-
specific aspects of clearance prediction algorithms (IVIVE) may be identified. 
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Materials and Methods 
Chemicals. Ritonavir, indinavir sulfate, saquinavir mesylate, nelfinavir mesylate were 
obtained from Hetero Drugs Limited (Hyderabad, India). Atazanavir was provided by 
Bristol-Myers Squibb (New Brunswick, NJ) and amprenavir, darunavir, lopinavir and 
tipranavir were obtained through the NIH AIDS Reagent Program. William’s E medium, 
Hanks’ Balanced Salt Solution (HBSS), L-glutamine, Fetal Bovine Serum (FBS), 
penicillin-streptomycin mixture (contains 10,000 IU potassium penicillin and 10,000 µg 
streptomycin sulfate per ml in 0.85% saline) and Trypsin EDTA were purchased from 
Lonza SPRL (Verviers, Belgium). HEPES (4-(2- hydroxyethyl)-1-piperazine-
ethanesulfonic acid) was purchased from MP Biochemical (Illkirch, France). Mineral oil 
was purchased from Acros organics (Thermo Scientific, Geel, Belgium). Collagenase 
(Type IV). Cyclosporin A, NADPH, Glucose-6-phosphate, MgCl2 and silicon oil were 
obtained from Sigma-Aldrich (Schnelldorf, Germany).  
Animals. All rats were housed according to the Belgian and European laws, guidelines 
and policies for animal experiments, housing and care in the central animal facilities of 
the university. The Institutional Ethical Committee for Animal Experimentation granted 
approval for this project. 
Isolation of rat hepatocytes. Hepatocytes were isolated from male Wistar (170 – 200 g) 
rats using a 2-step collagenase perfusion, as described previously.20 After isolation, cells 
were centrifuged (50 g) for 3 min at 4°C and the pellet was re-suspended in William’s E 
medium supplemented with 5 % FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 
µg/ml streptomycin. Hepatocytes were counted using a hemocytometer and cell viability 
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(> 90 %) was determined using Trypan blue exclusion. Freshly-isolated rat hepatocytes 
were re-suspended in Krebs-Henseleit Buffer (NaCl 130 mM, KCl 5.17 mM, CaCl2 1.2 
mM, MgCl2 1.2 mM, HEPES 12.5 mM, glucose 11.1 mM, Na-pyruvate 5 mM; pH 7.4) 
and kept on ice until start of the experiment. 
Uptake experiments with suspended hepatocytes. All experiments with suspended 
hepatocytes were conducted as described previously.14 Briefly, 500 µl of a double-
concentrated cell suspension (2 million cells/ml) was pre-incubated for 10 min at 37°C. 
Subsequently, 500 µl of a double-concentrated substrate solution (2 µM) was added to 
initiate the incubation at 37°C (or 4°C to determine the non-saturable uptake component). 
After an incubation period of 30 sec, triplicate 200 µl aliquots of the suspension were 
immediately transferred to 1.5 ml ice-cold microcentrifuge tubes, containing 700 µl of an 
oil layer (silicone / mineral oil mixture; density, 1.015) above 300 µl of 8 % NaCl 
solution. Subsequently, the tubes were centrifuged for 2 min at 16,000 g using a tabletop 
centrifuge (Eppendorf 5415 C, Hamburg Germany). After freezing microcentrifuge tubes 
in dry ice, the conical tube ends were cut and the contents diluted in 300 µl of a 70/30 % 
methanol/water mixture. Samples were stored at -20 °C until analysis. 
Preparation of rat liver microsomes (RLM). Briefly, three male Wistar rats (197-200 
g) were fasted for 24 h prior to preparation of RLM. After rats were anesthetized with an 
intraperitoneal injection of 120 mg/kg of ketamine and 24 mg/kg xylazine, the livers were 
perfused with ice-cold oxygentated homogenization buffer (5 mM 3-(N-morpholino)-
propanesulfonic acid MOPS, 1 mM EDTA, 250 mM sucrose, pH 7.4) to remove all 
blood. Subsequently, the livers were excised, minced with surgical scissors and added to 
ice-cold homogenization buffer (3 mL/g tissue). The tissue mixture was further 
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homogenized in a glass/Teflon© potter at 4°C. The pooled tissue solution was sampled 
for CYP content determination and centrifuged (4000 g) for 10 min at 4°C. After 
suspending the resulting pellet with homogenization buffer and repeating the 
centrifugation step, the supernatants were combined and transferred to polycarbonate 
ultracentrifuge tubes (Fisher Scientific, Landsmeer, Netherlands). This solution was 
subjected to another centrifugation step (15,000 g) for 20 min at 4°C, after which the 
pellet was discarded and the supernatant was ultra-centrifuged (150,000 g) for 70 min at 
4°C. The resulting microsomal pellet was washed with homogenization buffer and 
ultracentrifugation was repeated (150,000 g) for 35 min at 4°C. The microsomal pellet 
was homogenized in microsomal storage buffer (5 mM MOPS, 1 mM EDTA, 20 % w/v 
glycerol) with a glass/Teflon© potter homogenizer (2-3 up- en downstrokes, 800 rpm). A 
sample of the microsomes was taken for protein content determination and aliquots (500 
µL) were stored at -80°C. 
Determination of metabolic clearance using rat liver microsomes. Incubations were 
performed in 48-well plates in a Thermomixer (Eppendorf AG, Hamburg, Germany) set 
at 37 °C and 350 rpm in a volume of 400 µL. Pooled rat liver microsomes were diluted in 
phosphate buffer (100 mM, pH 7.4) containing glucose-6-phosphate (3 mM) and MgCl2 
(3 mM). Parent depletion by rat liver microsomes (0.025 – 0.25 mg protein/ ml) was 
measured in triplicate incubations over a range of substrate concentrations (0.02 – 5 µM). 
After a pre-incubation period of 10 min, NADPH (1 mM) was added to initiate the 
reaction. To terminate the reaction, triplicate samples (75 µL) were quenched at 0, 10, 20 
and 30 min by adding them to acetonitrile (75 µL) containing the internal standard. 
Samples were stored at -20 °C until analysis by mass spectrometry.  
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Determination of in vivo blood clearance of HIV PI in rats. The in vivo blood 
clearance Clin vivo, obs of HIV PI was determined in male Wistar rats (350 – 420 g). HIV PI 
dissolved in 1:1:2 mixtures of ethanol:DMSO:saline were administered intravenously via 
the lateral tail vein at 10 mg/kg (except for SQV; 5 mg/kg). The administered volume 
was 1 ml/kg. Blood samples (200 µL) were collected from the opposite lateral tail vein at 
5, 10, 20, 30, 60, 120, 180 and 240 min after dosing. Additionally, plasma samples were 
taken after 30, 60 and 120 min to determine the total blood-plasma drug concentration 
ratio Cb/Cp.  Blood and plasma samples were stored at -20 °C until analysis. 
Determination of unbound fraction in microsomal buffer. The unbound fraction in 
microsomal buffer was determined by equilibrium dialysis using HTD96b from 
HTDialysis, LLC (Gales Ferry, CT, US). The dialysis membranes were hydrated 
according to the manufacturer’s instructions. The donor and acceptor compartment were 
filled with microsomal buffer containing the HIV protease inhibitor (10 µM) and PBS, 
respectively. Samples (n = 6) of both compartments were taken after 6 h and were stored 
at -20 °C until analysis. 
Sample preparation and analysis. Samples obtained from liver microsomes and 
suspended rat hepatocytes were vortexed and centrifuged at 10,000 g for 10 min. Blood 
and plasma samples (30 µL) were diluted in 120 µL of water, followed by the addition of 
300 µL of acetonitrile (containing the internal standard). Subsequently, samples were 
vortexed and centrifuged at 14,000 g for 10 min at room temperature. For all samples, the 
supernatant obtained after sample preparation was directly injected into the HPLC-
tandem mass spectrometry system.  
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Analysis of HIV protease inhibitor was performed with a Thermo Scientific (San Jose, 
USA) LC–MS/MS system comprising an Accela® autosampler, an Accela® pump and a 
TSQ Quantum Access® triple quadrupole mass spectrometer equipped with an 
electrospray ionization (ESI) source. A Kinetex® XB - C18 column (50 mm ! 2.1 mm, 
2.6 µm), protected by a SecurityGuard ULTRA precolumn (Phenomenex, The 
Netherlands) was used for all chromatographic separations. The mobile phase consisted of 
a 0.5 mM ammonium acetate buffer (pH 3.5) (A) and methanol (B). Gradient elution at a 
constant flow rate of 400 µL/min was performed as follows: 95 % A decreased linearly to 
5 % A in 2 min; constant flow of 5 % A for 1 min; linear increase back to 95 % A in 10 
sec; re-equilibration for 1.0 min with 95 % A before the next injection. The total run time 
was 4.0 min and the injection volume was 10 µL (partial loop mode). The column oven 
and the autosampler tray temperature were set at 30° and 15 °C, respectively. The mass 
spectrometer was operated in the positive electrospray mode. The spray voltage was 3000 
V and argon was used as the collision gas at a pressure of 1.5 mTorr. The mass 
spectrometer was operated in a 3-channel selected reaction monitoring (SRM) mode with 
a scan time of 100 ms. Transitions monitored, automatically optimized parameters and 
retention times are listed in Supplemental Table 1. Data acquisition and peak integration 
were performed with Xcalibur software Thermo Scientific (San Jose, USA). 
Data Analysis. 
Uptake clearance data. Net uptake values were obtained by subtracting uptake in rat 
hepatocytes at 4°C from total uptake at 37°C. Subsequently, active, passive and total 
uptake clearance values (µL/min/million cells) were calculated by dividing the net uptake, 
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passive uptake or total uptake (pmol/min/million cells) by the corresponding substrate 
concentration, respectively.  
Metabolic clearance data. For metabolic drug depletion experiments, the log of the drug 
concentration was plotted in function of time and the elimination constant was calculated 
by fitting a single exponential decay. This elimination constant was used to calculate the 
half-life of the metabolic turn-over, which was further converted to the apparent intrinsic 
metabolic clearance (µl/min/mg protein) Clapp int, met according to following equation:21 !"!""!!"#,!"# != ! !.!"#!!/! !× ! !"#$%&'!("!!"#$%&!"!!"#$%&'  (1) 
Intrinsic metabolic clearance values were corrected for the unbound fraction fumic to 
obtain the intrinsic metabolic clearance Clint,met.  
In vivo pharmacokinetic data. In vivo pharmacokinetic parameters were calculated using 
non-compartmental analysis. Both AUC (area under the curve of the blood concentration 
– time plot) and AUMC (area under the curve when plotting the blood concentration x 
time versus time) were calculated using the trapezoidal rule and extrapolated to infinity 
with the terminal elimination rate constant λ. In vivo blood clearance (regarded as the 
hepatic clearance by assuming that the urinary excretion of HIV PI is negligible) and 
distribution volume were calculated according to following equations: 
Cl! = DoseAUC !!!!!!!(2)!!!!!!!!!!!!!!!!!!!!!!!!!!!" = !Cl!k !!!!!!!!!!!!!!!!!!!(3)!! 
The mean residence time (MRT) was calculated according to following equation:  
MRT = AUMCAUC !!!!!!!!!!!!!!!!!!!!!!!!!!(4)!!!!!!!!!!!!!!! 
In vitro – in vivo extrapolations. To evaluate the rate-limiting step in the overall hepatic 
elimination of HIV PI, the experimentally determined in vivo clearance of HIV PI was 
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predicted based on uptake data only, metabolism data only or a combination of both. 
Therefore, the determined in vitro intrinsic uptake or metabolic clearance values were 
first scaled to the intrinsic in vivo clearance by following reported scaling factors; values 
used for hepatocellularity and MPPGL were 120 ! 106 cells/g liver and 46 mg protein/g 
liver, respectively.22,23 The rat liver weight/kg body weight was determined in house and 
amounted to 40 g liver/kg. According to the well-stirred model, the intrinsic in vivo 
clearance values were converted to in vivo blood Clearance (ClB) values according to 
following equations;11,24  !"! = ! !!!×!!"!! !×!!"!"#,!"#!!! !!!!! ×!!"!"#,!"#! (5) 
!"! = ! !!!×!!"!! !×!!"!"#,!"#!!"!#$!!! !!"!! ×!!"!"#,!"#!!"!#$! (6) 
!"! = ! !!!×!!"!! !×!!"!"#,!"#!!"!#$!×!!"!"#,!"#!!!×! !"!"#,!"#!!!"!"#,!"#! "##$%& ! !(!"!! ×!!"!"#,!"#!!"!#$!×!!"!"#,!"#) (7) 
 
With QB, the blood flow in rats (55.2 ml/min/kg), Hc the hematocrit (0.56) and fu’B the 
fraction unbound in blood, calculated according to following equation; !"!! != !!"!× 1 − !" ×( 1!") (8) 
With fu, the free fraction in plasma and Rb the blood to plasma partitioning coefficient. 
Interaction simulations. To simulate the impact of interaction with active hepatic uptake 
of HIV PI, active uptake clearance was arbitrarily set at 10 or 500 % of the experimentally 
determined control value. Subsequently, the impact of inhibition and induction of active 
uptake transport on overall hepatic clearance was calculated by calculating the 
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corresponding in vivo hepatic clearance according to equation 7. Hepatic clearance values 
under the simulated conditions were expressed as a percentage of the calculated clearance 
values under control conditions.  
Statistics. The data analysis tool in Microsoft Excel 2010 (t-test, p < 0.05) was used to 
evaluate statistical differences between uptake under control condition and the presence of 
inhibitors. 
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Results  
Uptake of HIV PI in suspended rat hepatocytes. 
The passive and active uptake clearance values of all HIV PI in suspended rat 
hepatocytes are summarized in Table 1. For all HIV PI, the total uptake clearance at 37 
°C was significantly reduced when experiments were conducted at 4 °C. The relative 
contribution of the passive uptake in the total uptake of HIV PI ranged from 8 % for 
indinavir and atazanavir to 58 % for nelfinavir. Passive uptake clearance was positively 
correlated (R2 = 0.7) with LogP, as illustrated in Supplemental Figure 1.  
To further illustrate the involvement of carrier-mediated transport in the hepatic uptake of 
HIV PI, the effect of the non-specific inhibitor cyclosporin A (5 µM) on the hepatic 
uptake of indinavir and atazanavir was studied (Supplemental Figure 2). Cyclosporin is 
known to inhibit both uptake and efflux transporters as well as metabolizing enzymes.25–
28  However, under the experimental conditions used in this study (e.g. experiments in 
suspended hepatocytes at short time points), minimal impact of CYP-mediated 
metabolism or involvement of efflux transporters is assumed. In addition, the possible 
effects of cyclosporin A on metabolism or efflux would have implied increased substrate 
uptake. Instead, cyclosporin A significantly decreased the uptake of indinavir and 
atazanavir under control conditions by 44 % and 46 %, respectively.  
Metabolic clearance of HIV PI in rat liver microsomes. 
The intrinsic metabolic clearance Clint, met of HIV PI was determined in pooled rat liver 
microsomes (Supplemental Figure 3). Metabolic parameters describing Michaelis-
Menten type kinetics were obtained for seven HIV PI and are summarized in Table 2. 
The intrinsic metabolic clearance values for ritonavir and nelfinavir were taken from 
published data by Parker and Houston.19 Additionally, metabolic clearance was measured 
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at one concentration corresponding to the in vivo unbound blood concentration after a 
time window corresponding to the mean residence time (Table 3).  
In vivo pharmacokinetics of HIV PI in rats after intravenous administration. 
All HIV PI were formulated in a mixture of ethanol, DMSO and saline (ratio 1:1:2). To 
test the potential impact of DMSO on the in vivo clearance of HIV PI, the in vivo 
pharmacokinetics of indinavir dissolved in a mixture of ethanol, dextrose and water (ratio 
3:3:4) was also measured. There was no significant difference in in vivo blood clearance 
values or other pharmacokinetic parameters between both formulations (data not shown).  
All HIV PI were cleared rapidly in rats following intravenous administration. Blood 
concentration – time profiles are shown for all HIV PI in Supplemental Figure 4 and 
corresponding in vivo pharmacokinetic parameters are summarized in Table 4. In vivo 
blood clearance values ranged from 2.2 ± 0.4 ml/min/kg for tipranavir to 47.0 ± 1.1 
ml/min/kg for lopinavir.  
IVIVE of the hepatic clearance of HIV PI in rats 
The in vitro intrinsic clearance values for uptake (Clupt, active and Clupt, passive) and 
metabolism (Clint,met) were scaled to the whole liver by applying corresponding scaling 
factors (Table 5). Plasma protein binding and blood-to-plasma ratios were experimentally 
determined and are summarized in Table 6. Subsequently, these in vitro clearance values 
were extrapolated to the in vivo blood clearance based on the individual processes or the 
combination of both according to equations 5, 6 and 7, respectively. 
The relationship between the experimentally determined and predicted in vivo blood 
clearance of all HIV PI is shown in Figure 1. Based on uptake data only (Figure 1, panel 
A), a poor linear correlation (R2 = 0.25) between the reported and predicted in vivo 
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clearance was found. However, only for ritonavir the predicted in vivo blood clearance 
deviated by more than 2 fold from the experimentally determined value. Especially for 
indinavir, atazanavir, nelfinavir and saquinavir, extrapolated uptake clearance values in 
hepatocytes predicted the observed in vivo blood clearance well (max 1.2 fold 
difference). 
When IVIVE was based on full pharmacokinetic metabolism data (Figure 1, panel B), in 
vivo blood clearance values were over-estimated for all HIV PI. Moreover, all predicted 
in vivo blood clearance values (except for tipranavir) seemed to approach the hepatic 
blood flow. On the contrary, when IVIVE was based on intrinsic metabolic clearance 
values (Clint, met) determined in rat liver microsomes at one relevant concentration (= the 
unbound concentration at the mean residence time calculated from the in vivo profiles), a 
good correlation (R2 = 0.80) between the observed and predicted in vivo clearance values 
was observed (Figure 1, panel C). Except for ritonavir and tipranavir, clearance value 
estimates fell within a 1.5-fold range of the experimentally determined values.  
When both uptake and metabolism processes were taken into account (Figure 1, panel D), 
the correlation between reported and predicted in vivo hepatic clearance was comparable 
to that based on uptake data only (R2 = 0.25), with a fold deviation from the observed 
value ranging from 0.7 fold for tipranavir to 2 fold for ritonavir. 
To simulate the impact of interaction with active hepatic uptake on the hepatic clearance 
of HIV PI, the effect of inhibition and induction of the hepatic uptake was calculated and 
presented in Figure 2. The simulation showed that the hepatic Cl of atazanavir, indinavir, 
lopinavir and tipranavir decreased approximately by 60 % when active hepatic uptake is 
inhibited by 90 %. On the contrary, a limited decrease of the hepatic Cl for other HIV PI 
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is observed when active uptake was inhibited. The predicted effect of induction of 
transporter expression on the hepatic Cl of hepatocytes revealed a significant increase in 
the hepatic Cl of tipranavir when hepatic uptake was 5 times increased, whereas only a 
limited effect was observed for other HIV PI. To evaluate potential species differences on 
the impact of active uptake inhibition, the relative contribution of hepatic uptake 
transport in the overall clearance for each individual HIV protease inhibitor was 
compared in rat and human (R2 = 0.74; Figure 3). The simulated effect of hepatic uptake 
inhibition (90 %) on the overall hepatic clearance of HIV PI showed great agreement in 
rat and human. Indeed, in both species the hepatic clearance values of lopinavir, 
atazanavir and tipranavir are predicted to be influenced by hepatic uptake inhibition. On 
the contrary, amprenavir and nelfinavir will most likely not be influenced by basolateral 
uptake transporter mediated drug – drug interactions as victim drugs.  
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Discussion 
Hepatic disposition of HIV protease inhibitors comprises of a complex network of 
multiple processes including transporter-mediated uptake/elimination and CYP-mediated 
metabolism.15,16,29 Consequently, interference with any of these processes may result in 
clinically relevant drug – drug interactions. The present study aimed to elucidate the rate-
limiting step in the overall hepatic clearance in rats and to evaluate the impact of hepatic 
uptake transport inhibition and induction for all marketed HIV PI.  
Both rat hepatocytes in suspension and sandwich-culture configuration represent useful in 
vitro model systems for the assessment of hepatic uptake.30–33 However, several 
publications have demonstrated that sandwich-cultured rat hepatocytes exhibit declining 
transport activity levels of most hepatic uptake transporters (belonging to the SLC gene 
family) in function of culture time.34 Therefore, hepatocytes in suspension were used in 
this study to investigate transporter-mediated uptake clearance of HIV PI.34 Uptake 
clearance values of all HIV PI, determined in suspended rat hepatocytes, were 
temperature-dependent (Table 1), suggesting the involvement of a carrier-mediated 
process in the hepatic uptake of HIV PI. Although the passive contribution may be partly 
influenced by alterations in membrane fluidity at 4 °C, the involvement of hepatic uptake 
transport proteins was further confirmed by the reduced hepatic uptake of indinavir and 
atazanavir in presence of the non-specific transporter inhibitor cyclosporin A 
(Supplemental Figure 2).35 Parameters describing Michaelis-Menten kinetics would have 
been preferred to calculate intrinsic uptake clearance values of HIV PI. However, initial 
uptake velocities showed no saturation over the concentration range tested for several PI 
(e.g. indinavir) (data not shown). Therefore, we determined the uptake clearance of all 
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HIV PI at 1 µM (Table 1), a concentration well below the previously reported Km values 
for nelfinavir, saquinavir and ritonavir.19 Literature data regarding hepatic uptake of HIV 
PI in rat hepatocytes is scarce. Yabe et al. observed active uptake clearance values of 873 
± 216 and 293 ± 153 µl/min/million cells in suspended rat hepatocytes for ritonavir and 
saquinavir, respectively.36 These data are comparable to our results and uptake clearance 
values reported by Parker and Houston.19 The latter study additionally reported a net 
uptake clearance for nelfinavir (2670 µl/min/million cells), which is approximately 13-
fold higher compared to our data.19 This discrepancy may result from differences in 
experimental design (one concentration versus full kinetic profiles) and methodology 
(presence of albumin in the incubation medium).  
Rat liver microsomes have shown to be a robust in vitro model system for the assessment 
of oxidative metabolism by CYP enzymes and for the prediction of hepatic metabolic 
clearance of large compound sets.7,37 In addition to liver microsomes, phase I drug 
metabolism can be determined in suspended hepatocytes, which offer the additional 
advantage that phase II conjugation reactions (e.g. glucuronidation) can also be studied.38 
However, it is well known that uptake transporters present in hepatocytes can increase 
metabolic clearance by elevating the concentration at the site of the metabolizing 
enzymes.12 Assuming that phase II conjugation pathways are not significantly influencing 
the overall elimination of HIV PI, a pooled batch of rat liver microsomes was used to 
study transporter-independent oxidative metabolism. Parameters describing Michaelis-
Menten type kinetics were obtained for seven HIV PI (Table 2). Due to low apparent Km 
values, analytical sensitivity limited accurate determination of the metabolic turnover rate 
at very low substrate concentrations for ritonavir and nelfinavir. Therefore, intrinsic 
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metabolic clearance values for these drugs were taken from literature.19 In this 
publication, the metabolic clearance value for saquinavir was comparable to the value 
obtained in the present study. 
Extrapolating in vitro metabolism data to gain quantitative predictions of the in vivo 
hepatic clearance has successfully been applied for compounds for which elimination is 
predominantly mediated by metabolic enzymes.7,39,40 Consistently, in vitro transport data 
have been used to accurately predict the in vivo clearance of drugs, for which hepatic 
uptake is the rate-limiting step in the overall hepatic clearance.9 However, the in vivo 
elimination of most drugs is defined by a complex interplay between transporters and 
metabolizing enzymes. Therefore, single parameter models have been expanded to more 
complex models, combining multiple processes of hepatic elimination.10,11,41–43 In the 
present study, we retrospectively predicted experimentally determined in vivo blood 
clearance with single process models (based on in vitro metabolism or uptake data) as 
well as with a model combining both processes to further elucidate the rate-limiting step 
in the overall hepatic elimination of HIV PI.12 Overall, IVIVE based on uptake data only 
resulted in a poor correlation (R2 = 0.25) between predicted and observed in vivo blood 
clearance values (Figure 1, panel A). The significant overestimation of the in vivo blood 
clearance for darunavir, amprenavir and ritonavir is consistent with the observation that 
IVIVE based on uptake clearance data derived from hepatocytes results in an 
overestimation of hepatic clearance.11 On the contrary, for other HIV PI (e.g. indinavir, 
nelfinavir, saquinavir and atazanavir) IVIVE resulted in a good quantitative prediction of 
the in vivo blood clearance values, suggesting that for these compounds hepatic uptake 
may be a more dominant process in the overall hepatic elimination in rats.  
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IVIVE using full Michaelis Menten profiles for metabolism in rat liver microsomes 
resulted in a poor correlation between predicted and observed in vivo blood clearance (R2 
= 0.47, Figure 1, Panel B). Interestingly, when single parameter IVIVE analysis was 
based on metabolism data performed at one concentration corresponding to the relevant 
in vivo concentration (= the unbound blood concentration at the mean residence time 
determined in the in vivo part of the present study) a good correlation (R2 = 0.80) was 
observed (Figure 1, Panel C). This suggests that at relevant in vivo conditions, high 
intracellular unbound concentrations are reached at which metabolizing enzymes appear 
to be (partially) saturated. Consequently, the use of metabolism data based on full in vitro 
concentration profiles in rat liver microsomes results in an overestimation of the hepatic 
in vivo clearance. Indeed, as already indicated previously by Parker and Houston, 
microsomal clearance values (determined as Vmax / Km) can be misleading in terms of the 
magnitude of the metabolic turnover in vivo.19 Compared to the approaches based on 
hepatic metabolism or uptake only, IVIVE based on both metabolism and transporter data 
showed a poor correlation between predicted and observed in vivo clearance values.  
Inhibition of hepatic uptake is widely accepted as a mechanism explaining important 
drug-drug interactions in humans. More recently, induction of hepatic uptake transporters 
has also been suggested to explain the effect of rifampicin on the pharmacokinetics of 
digoxin and glyburide.44,45 To assess the impact of hepatic uptake transport inhibition or 
induction, the sensitivity of overall Cl predictions towards alterations in active hepatic 
uptake Cl was evaluated for each individual HIV protease inhibitor (Figure 2). Because 
the extent of inhibition/induction of hepatic uptake in vivo is unknown, we anticipated a 
worst case scenario and evaluated conditions of 90 % inhibition or 5-fold induction. Our 
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data suggest that most HIV PI can be involved as victim drugs in drug – drug interactions 
in rats when active uptake is inhibited. Only for darunavir, amprenavir and nelfinavir, 
potent hepatic uptake inhibition is expected to marginally influence the hepatic Cl. Our 
simulations also showed that induction of hepatic uptake transporters may lead to an 
increased hepatic Cl of tipranavir. Interestingly, no effect of induction is predicted for 
other HIV PI, suggesting that the hepatic clearance of these HIV PI (e.g. indinavir, 
lopinavir and atazanavir) is blood-flow limited. 
Finally, when we compared the relative contribution of hepatic uptake transport in the 
overall clearance for each individual HIV protease inhibitor in rat and human (see 
companion paper De Bruyn et al., 2015), a good correlation (R2 = 0.74) between both 
species was observed (Figure 3). Indeed, when we simulated the effect of hepatic uptake 
inhibition on the overall clearance of HIV PI in rat and human, we noticed that in both 
species the hepatic clearance values of lopinavir, atazanavir and tipranavir are predicted 
to be influenced by hepatic uptake inhibition. On the contrary, amprenavir and nelfinavir 
are not expected to be influenced by uptake transporter mediated drug – drug interactions 
as victim drugs. The results for lopinavir are in good agreement with the increased 
plasma concentrations of lopinavir in presence of the 521 T>C gene polymorphism in 
SLCO1B1.29 
In conclusion, these results confirm a key role for metabolism in the hepatic clearance of 
most HIV PI in rats. In addition, hepatic uptake transport may be important for several 
HIV PI, suggesting a complex transporter-metabolism interplay for these compounds. 
Our findings also imply that transporter-mediated drug-drug interactions at the level of 
rat liver involving several of these HIV PI as victim drugs cannot be excluded. 
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FIGURE LEGENDS 
 
Supplemental Figure 1 
Relationship between LogP and passive uptake clearance for all HIV protease inhibitors 
in suspended rat hepatocytes. Passive uptake clearance values were experimentally 
determined at 4 °C and logP values were obtained from ChemSpider. 
Supplemental Figure 2 
Uptake of indinavir and atazanavir in suspended rat hepatocytes. Bars represent the 
uptake (1µM, 30 sec) determined at 37 °C (black bars), at 4 °C (open bars) or at 37 °C in 
the presence of cyclosporin A (5 µM, grey bars). * Statistically significant difference 
compared with control uptake determined at 37°C (p < 0.05). 
Supplemental Figure 3 
Relationship between metabolic rate and substrate concentration for all tested HIV PI in 
pooled rat liver microsomes. Points represent mean values (± SD) of triplicate 
incubations and the solid line represents the best fit to experimental data according to the 
Michaelis-Menten equation. 
Supplemental Figure 4 
Blood concentration – time profile of HIV PI following intravenous administration (10 
mg/kg, except for saquinavir; 5 mg/kg) to male Wistar rats. Points represent mean values 
(± SD) of triplicate incubations and the solid line represents the best fit to experimental 
data according to a one-compartmental model. 
Figure 1 
Relationship between the experimentally determined and calculated in vivo clearance of 
all HIV PI in rats. Clearance values (ml/min/kg) were predicted based on only in vitro 
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uptake clearance data (A), only concentration-velocity profile-based in vitro metabolism 
data (B), only in vitro metabolic clearance data determined at one clinically relevant 
concentration (C) or a combination of both uptake and metabolic clearance data (D). 
Figure 2 
Simulation of the impact of interaction with hepatic uptake on the hepatic clearance of 
HIV PI. Hepatic clearance values of HIV PI are shown under conditions of 90 % 
inhibition (and/or down-regulation) (open bars) or 5-fold induction (and/or activation) 
(grey bars) of the hepatic uptake Cl and are expressed as a percentage of the calculated in 
vivo clearance under control conditions.  
Figure 3 
Correlation between rat and human regarding the simulated effect of hepatic uptake 
inhibition (90 %) on the overall hepatic clearance of HIV PI. Values represent predictions 
of residual hepatic clearance under conditions of 90 % inhibition of hepatic uptake Cl for 
each HIV PI in both species, and are expressed relative to the determined in vivo 
clearance for rat and human, respectively. 
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Supplemental Table 1 
Transitions monitored, optimized parameters and retention time for LC-MS/MS analysis.  
Substrate Transition CT VT SG AG ISG CE RT (min) 
Amprenavir 506.3 ! 245.2 270 300 60 2 30 17 2.68 
Atazanavir 705.4 ! 168.1 170 300 50 0 40 43 3.16 
Darunavir 548.3 ! 392.3 275 300 30 5 20 12 2.7 
Lopinavir 629.4 ! 155.2 170 300 50 0 40 38 3.4 
Indinavir 614.5 ! 421.3 275 300 50 5 10 32 2.94 
Nelfinavir 568.3 ! 330.1 275 300 50 10 10 30 3.3 
Ritonavir 
 
 
 
721.3 !140.0 
721.3 !197.0 
721.3 !268.1 
721.3 !296.0 
220 
 
 
 
300 
 
 
 
60 
 
 
 
10 
 
 
 
25 
 
 
 
57 
35 
24 
16 
3.19 
 
 
 
Saquinavir 671.5 ! 570.4 275 300 60 55 10 29 3.25 
Tipranavir 
 
603.3 ! 411.1 
603.3 ! 585.4 
280 
 
300 
 
60 
 
0 
 
10 
 
21 
14 
3.34 
 
CT, capillary temperature; VT, vaporizing temperature; SG, sheet gas; AG, auxiliary gas; ISG, 
ion sweep gas; CE, collision energy; RT, retention time. All parameters (except for retention 
time) are expressed in arbitrary units. 
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Table 1 
Uptake clearance values of HIV PI determined in suspended rat hepatocytes. The relative 
uptake, calculated as the percentage of the active/passive uptake to the total uptake, is 
shown in parentheses. 
 Uptake clearance in suspended rat hepatocytes  (µl/min/million cells) 
Compound Clupt, active Clupt, passive Clupt, total 
Amprenavir 
 
180.5 ± 26.1  
(69.9) 
77.7 ± 4.7  
(30.1) 
258.2 ± 25.7 
 
Atazanavir 
 
194.5 ± 43.1 
(91.3) 
18.5 ± 6.0  
(8.7) 
213 ± 42.7 
 
Darunavir 
 
163.3 ± 15.4 
(82.4) 
34.8 ± 11.8  
(17.6) 
198.2 ± 9.8 
 
Indinavir 
 
83.8 ± 4.4 
(92.2) 
7.1 ± 3.5  
(7.8) 
90.9 ± 2.8 
 
Lopinavir 
 
599.4 ± 29.9 
(89.6) 
69.6 ± 17.4  
(10.4) 
669.0 ± 24.3 
 
Nelfinavir 
 
209.7 ± 36.4 
(42.5) 
284.2 ± 27.2  
(57.5) 
493.9 ± 24.2 
 
Ritonavir 
 
474.3 ± 38.1 
(79.6) 
121.2 ± 23.2  
(20.4) 
595.5 ± 30.2 
 
Saquinavir 
 
195.7 ± 19.4 
(68.4) 
90.6 ± 13.6  
(31.6) 
286.3 ± 13.9 
 
Tipranavir 
 
324.8 ± 26.3 
(70.3) 
137.2 ± 16.8  
(29.7) 
461.9 ± 20.3 
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Table 2 
 
Michaelis-Menten parameters for metabolism of HIV PI in pooled rat liver microsomes.  
 
Substrate Km  (nM)  
Vmax  
(pmol/min/mg protein) 
Clapp int, met 
(ml/min/mg protein) 
Clint, met  
(ml/min/mg protein) 
Amprenavir 162 ± 60 163 ± 17 1.0 1.4 
Atazanavir 478 ± 84 607 ± 28 1.4 1.8 
Darunavir 157 ± 21 190 ± 9 1.2 2.5 
Indinavir 77 ± 15 154 ± 15 2.0 2.5 
Lopinavir 236 ± 88 3220 ± 316 13.6 24.6 
Nelfinavir N.D. N.D. N.D. 27.4a 
Ritonavir N.D. N.D. N.D. 16.8a 
Saquinavir 81 ± 13 1040 ± 54 12.8 21.3 
Tipranavir 114 ± 36 588 ± 57 5.2 12.7 
N.D., not determined; a Published data.19 
35"
"
Table 3 
 
Metabolic clearance values of HIV PI measured in pooled rat liver microsomes at one 
concentration corresponding to the in vivo blood concentration at the mean residence 
time. 
Substrate MRT (min) 
Unbound blood conc after 
time window corresponding 
to MRT (nM) 
Clint, met  
(µl/min/mg protein) 
Amprenavir 37.9 ± 8.4 2382 52 
Atazanavir 105.9 ± 65.5 66.7 1200 
Darunavir 41.1 ± 1.1 1465.7 120 
Indinavir 31.6 ± 4.5 2166 74 
Lopinavir 61.4 ± 12.2 42.3 11564 
Nelfinavir 70.6 ± 2.8 72.3 4302 
Ritonavir 156.2 ± 31.9 100.5 335 
Saquinavir 76.6 ± 17.1 40.5 12312 
Tipranavir 116.9 ± 3.8 11.5 6534 
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Table 4 
 
Pharmacokinetic parameters of HIV PI after intravenous administrations in rats. HIV PI 
were dissolved in a mixture of ethanol, DMSO and saline (ratio 1:1:2) and intravenously 
administered via the lateral tail vein at 10 mg/kg (except for SQV; 5 mg/kg). 
Compound Blood clearance Clb Distribution volume Vd 
 (ml/min/kg) (ml) 
Amprenavir 24.0 ± 4.8 345.2 ± 118.7 
Atazanavir 36.7 ± 15.4 1166.5 ± 273.1 
Darunavir 29.0 ± 6.2 452.8 ± 99.2 
Indinavir 35.4 ± 8.5 418.3 ± 150.4 
Lopinavir 47.0 ± 1.1 1204.4 ± 236.1 
Nelfinavir 36.9 ± 11.6 945.6 ± 230.9 
Ritonavir 12.0 ± 2.3 755.3 ± 97.6 
Saquinavir 36.1 ± 7.4 1081.5 ± 111.6 
Tipranavir 2.2 ± 0.4 106.9 ± 16.8 
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Table 5 
Scaled intrinsic uptake and metabolic clearance value for all HIV PI. The in vitro 
intrinsic clearance values for uptake (Clupt, active and Clupt, passive) and metabolism (Clint,met) 
were scaled to the whole liver by applying reported scaling factors.  
 Scaled intrinsic clearance (ml/min/kg) 
 Uptake Metabolism 
Compound Active Passive Michaelis-Menten at MRTa 
Amprenavir 866 ± 125 373 ± 22 2496 95.6 
Atazanavir 934 ± 207 89 ± 29 3282 2208.6 
Darunavir 784 ± 74 167 ± 57 4589 220.6 
Indinavir 402 ± 21 34 ± 17 4683 135.6 
Lopinavir 2877 ± 143 334 ± 84 45338 21277.5 
Nelfinavir 1007 ± 175 1364 ± 131 50377 7915.6 
Ritonavir 2277 ± 183 582 ± 112 31003 616.5 
Saquinavir 939 ± 93 435 ± 65 39242 22653.9 
Tipranavir 1559 ± 126 658 ± 81 23407 12022.5 
a refers to the scaled intrinsic clearance measured for a concentration observed at time 
equal to the mean residence time (MRT) in vivo. 
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Table 6 
Experimentally determined fraction unbound in plasma and blood-plasma portioning 
ratio for all HIV PI. Fraction unbound in blood was calculated according to equation 8. 
 Protein binding 
Compound fuplasma Rb fu’blood 
Amprenavir 0.32 0.87 0.16 
Atazanavir 0.075 0.85 0.04 
Darunavir 0.3 0.67 0.2 
Indinavir 0.49 1.2 0.19 
Lopinavir 0.021 0.62 0.02 
Nelfinavir 0.035 0.85 0.02 
Ritonavir 0.037 0.70 0.02 
Saquinavir 0.051 0.82 0.03 
Tipranavir 0.001 0.62 0.0004 
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Figure 3
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